<DOC>
	<DOCNO>NCT01408303</DOCNO>
	<brief_summary>The primary objective evaluate efficacy add Epanova ( 2 g 4 g daily ) optimal statin monotherapy lower non-high-density lipoprotein ( non-HDL ) cholesterol subject persistent hypertriglyceridemia high risk cardiovascular disease .</brief_summary>
	<brief_title>EPANOVA Combined With STATIN PATIENTS With HYPERTRIGLYCERIDEMIA Reduce Non-HDL CHOLESTEROL</brief_title>
	<detailed_description>The primary efficacy variable serum non-HDL cholesterol . The primary endpoint difference mean percent change baseline end-of-treatment non-HDL cholesterol placebo 2g/day 4g/day Epanova group . Baseline define average Visits 2 , 3 4 ( Weeks -2 , -1 0 ) end-of-treatment average Visits 5 6 ( Weeks 5 6 ) .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>1 . Men woman , ≥18 year age . 2 . Fasting triglyceride ( TG ) level ≥200 mg/dL &lt; 500 mg/dL . 3 . The subject high risk future cardiovascular event . 4 . The subject treat statin near LDLC goal . 1 . Allergy intolerance omega3 fatty acid omega3acid ethyl ester . 2 . Use fibrates , bile acid sequestrants , niacin analogue ( great 200 mg/d ) screening . 3 . Use simvastatin 80 mg Vytorin10/80 mg screening . 4 . Use eicosapentaenoic acid ( EPA ) docosahexaenoic acid ( DHA ) product . 5 . Use supplement purpose lower plasma cholesterol screen . 6 . Use weight loss drug program screen . 7 . Use erythromycin , telithromycin , clarithromycin , cyclosporine , itraconazole , ketoconazole , protease inhibitor , nefazodone screen . 8 . Use anticoagulant screen . 9 . Use oral injected corticosteroid screen . 10 . Use tamoxifen , estrogens , progestin , testosterone , stable &gt; 4 week Visit 1 , unstable screening . 11 . Use &gt; 750 mL/d grapefruit juice screen . 12 . Known lipoprotein lipase impairment deficiency , apolipoprotein CII deficiency familial dysbetalipoproteinemia . 13 . History pancreatitis . 14 . Type I diabetes mellitus , use insulin , HbA1c &gt; 10 % Visit 1 . 15 . Poorly control hypertension 16 . Uncontrolled hypothyroidism , thyroid stimulate hormone ( TSH ) &gt; 1.5xULN Visit 2 . 17 . Recent history current significant nephrotic syndrome , pulmonary , hepatic , biliary , gastrointestinal immunologic disease . 18 . History cancer ( except nonmelanoma skin cancer , carcinoma situ cervix ) within previous two year . 19 . Females pregnant , plan pregnant study period , lactate , woman childbearing potential use acceptable method contraception . 20 . Creatine kinase &gt; 5.0 time upper limit normal ( ULN ) ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 time ULN Visit 2 . 21 . Current recent history ( past 12 month ) drug alcohol abuse . 22 . Exposure investigational agent within 4 week prior Visit 1 . 23 . Any condition investigator believe would interfere subject 's ability provide inform consent , comply study instruction , might confound interpretation study result put subject undue risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>dyslipidemia</keyword>
	<keyword>hyperlipidemia</keyword>
	<keyword>cardiovascular risk</keyword>
</DOC>